Your browser doesn't support javascript.
loading
Pilot study of a decision aid on BRCA1/2 genetic testing among Orthodox Jewish women.
Trivedi, Meghna S; Manley, Haley; Yi, Haeseung; Silverman, Thomas; Chung, Wendy K; Appelbaum, Paul S; Starck, Rebecca; Schecter, Isaac; Kukafka, Rita; Crew, Katherine D.
Afiliação
  • Trivedi MS; Department of Medicine, Vagelos College of Physicians and Surgeons, Columbia University, 161 Fort Washington Avenue HIP 10, New York, NY, 10032, USA. mst2134@cumc.columbia.edu.
  • Manley H; College of Law, DePaul University, Chicago, IL, USA.
  • Yi H; Department of Health and Behavior Studies, Teachers College, Columbia University, New York, NY, USA.
  • Silverman T; Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Chung WK; Department of Pediatrics, Boston Children's Hospital, Boston, MA, USA.
  • Appelbaum PS; Department of Psychiatry, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
  • Starck R; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY, USA.
  • Schecter I; Institute for Applied Research and Community Collaboration (ARCC), Spring Valley, NY, USA.
  • Kukafka R; Achieve Behavioral Health, Monsey, NY, USA.
  • Crew KD; Department of Biomedical Informatics, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, USA.
Fam Cancer ; 2024 Apr 12.
Article em En | MEDLINE | ID: mdl-38609522
ABSTRACT

INTRODUCTION:

Orthodox Jewish women face unique social, cultural, and religious factors that may influence uptake of BRCA1/2 genetic testing. We examined the impact of a web-based decision aid (DA) on BRCA1/2 genetic testing intention/completion among Orthodox Jewish women. We conducted a single-arm pilot study among 50 Orthodox Jewish women who were given access to a web-based DA entitled RealRisks and administered serial surveys at baseline and 1 and 6 months after exposure to the DA. Descriptive statistics were conducted for baseline characteristics and study measures. Comparisons were made to assess changes in study measures over time. Fifty Orthodox Jewish women enrolled in the study with a mean age of 43.9 years (standard deviation [SD] 14.6), 70% Modern Orthodox, 2% with personal history of breast cancer, and 68% and 16% with a family history of breast or ovarian cancer, respectively. At baseline, 27 (54%) participants intended to complete genetic testing. Forty-three participants (86%) completed RealRisks and the 1-month survey and 38 (76%) completed the 6-month survey. There was a significant improvement in BRCA1/2 genetic testing knowledge and decrease in decisional conflict after exposure to the DA. At 1 month, only 20 (46.5%) completed or intended to complete genetic testing (p = 0.473 compared to baseline). While the DA improved genetic testing knowledge and reduced decisional conflict, genetic testing intention/completion did not increase over time. Future interventions should directly address barriers to BRCA1/2 genetic testing uptake and include input from leaders in the Orthodox Jewish community. GOV ID NCT03624088 (8/7/18).
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article